Ionis to Acquire Remaining Stake in Akcea Therapeutics for $18.5/share
Shots:
- Ionis will acquire all the outstanding shares of Akcea common stock it does not already own- ~24%- for $18.15/share in cash- making a total deal value as $500M. The transaction is expected to be completed in Q4’20
- Following the completion of the acquisition- Ionis will get access to Akcea's rich pipeline and commercial products which will strengthen its financial position and supports its capital allocation strategy
- Ionis will gain full access to Akcea's cash on hand of ~$390M as of June 30- 2020- and future cash flows to further invest in the company's future and will achieve meaningful cost synergies
Ref: PRNewswire | Image: Rawpixel
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com